Daiichi Sankyo Company, Limited (TYO: 4568)
Japan
· Delayed Price · Currency is JPY | Market Cap | 8.48T |
| Revenue (ttm) | 1.76T |
| Net Income (ttm) | 250.40B |
| Shares Out | 1.89B |
| EPS (ttm) | 130.80 |
| PE Ratio | 34.27 |
| Forward PE | 45.57 |
| Dividend | 60.00 (1.33%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 4,598,500 |
| Open | 4,516.00 |
| Previous Close | 4,502.00 |
| Day's Range | 4,460.00 - 4,550.00 |
| 52-Week Range | 3,805.00 - 6,257.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 31, 2024 |
About Daiichi Sankyo Company
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhi... [Read more]
Financial Performance
In 2023, Daiichi Sankyo Company's revenue was 1.60 trillion, an increase of 25.28% compared to the previous year's 1.28 trillion. Earnings were 200.73 billion, an increase of 83.84%.
Financial StatementsNews
England Pricing Talks Fail on Astra, Daiichi Breast Cancer Drug
AstraZeneca Plc and Daiichi Sankyo Co Ltd have once again failed to reach an agreement with England’s drug pricing regulator on the cost of a breast cancer medicine.
Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will highlight new clinical research and real-world data from seven abstracts for TURALIO® (pexidartinib) at the Connective Tissue Onco...
ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product
Daiichi Sankyo (TSE:4568) and AstraZeneca (NASDAQ: AZN) have been awarded The Galien Foundation 2024 Prix Galien USA Award for Best Biotechnology Product for ENHERTU ® (fam-trastuzumab deruxtecan-nxk...
Daiichi Sankyo Company, Limited (DSKYF) Q2 2025 Earnings Call Transcript
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ETCompany ParticipantsHiroyuki Okuzawa -...
Daiichi Sankyo COO: Partnerships with Merck & AstraZeneca going very well
Daiichi Sankyo's chief operating officer, Hiroyuki Okuzawa speaks about the company's drug pipeline and alliances with global pharmaceutical firms.
Daiichi Sankyo Company, Limited 2024 Q2 - Results - Earnings Call Presentation
Daiichi Sankyo Eyes Newer Cancer Drugs to Stave off Rivals
Drugmaker Daiichi Sankyo is working to boost production of its newer-generation cancer therapies that target diseased cells, across Japan, Europe and the US.
Daiichi Sankyo and AstraZeneca's Enhertu Receives Priority Review from FDA for HER2 Low Breast ...
Daiichi Sankyo and AstraZeneca's Enhertu Receives Priority Review from FDA for HER2 Low Breast Cancer
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
Based on DESTINY-Breast06 Phase III trial which demonstrated a statistically significant and clinically meaningful progression-free survival benefit for ENHERTU If approved, AstraZeneca and Daiichi Sa...
AstraZeneca antibody drug candidate fails to meet overall survival goal in breast cancer
AstraZeneca and Daiichi Sankyo face setback as breast cancer drug fails to show significant overall survival benefit in final analysis. Read more here.
Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
Survival results for Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan in TROPION-Breast01 did not achieve statistical significance versus chemotherapy Trial previously met the dual primary endp...
Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance
Daiichi Sankyo's (DSNKY) ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
Merck, Daiichi post late-stage trial win for novel lung cancer therapy
Merck (MRK) and Daiichi Sankyo's (DSNKY) lung cancer drug, patritumab deruxtecan hits the primary endpoint in a Phase 3 trial as a second-line therapy. Read more here.
Daiichi Sankyo and Merck's cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug met the main goal in a late-stage study in patients with lung cancer.
ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases
Daiichi Sankyo and AstraZeneca's ENHERTU achieved a 61.6% progression-free survival rate at one year in patients with active or stable brain metastases in DESTINY-Breast12 Largest prospective trial of...
ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases.
AstraZeneca Shares Set For Worst Week in 14 Months on Sell Calls
AstraZeneca Plc shares are on track for their biggest weekly decline since July 2023, after a disappointing update for the British drugmaker’s experimental lung cancer medicine with partner Daiichi Sa...
Daiichi Sankyo Plunges on Mixed Trial Result of Lung Cancer Drug
Daiichi Sankyo Co. shares drop as much as 10.4% on Tuesday, the most since Aug. 5, after its lung cancer drug with AstraZeneca showed mixed results in a phase 3 trial.
Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Unveils New Research Across Industry-Leading ADC Portfolio in Multiple Cancers at WCLC and ESMO.
Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining...
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer
Daiichi Sankyo and AstraZeneca's ENHERTU has now been granted eight Breakthrough Therapy Designations with latest based on DESTINY-Breast06 phase 3 trial results Eleventh Breakthrough Therapy Designat...
Daiichi Sankyo Company, Limited (DSKYF) Q1 2024 Earnings Call Transcript
Daiichi Sankyo Company, Limited (OTCPK:DSKYF) Q1 2024 Earnings Conference Call July 31, 2024 5:00 AM ET Company Participants Toshinori Agatsuma - Head of R&D Division Koji Ogawa - Head of Global Corpo...
Daiichi Sankyo Opens New Affiliate for Oncology in Greece
ATHENS, Greece--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that it has opened a new affiliate for its oncology business in Athens, Greece. The establishment highlights the company's s...
Arbitration Dispute Between Daiichi Sankyo and Seagen Ends
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--A dispute between Daiichi Sankyo Co., Ltd. (TSE: 4568) and Seagen Inc. is now concluded and Seagen has paid Daiichi Sankyo approximately U.S. $47 million ...
Daiichi Sankyo Is Riding The ADC Revolution To Billions In Future Revenue
Daiichi Sankyo is poised to play its part in revolutionizing cancer treatments with its portfolio of antibody-drug conjugates, that target $15 billion-plus annual revenue opportunities. Enhertu, the p...